Advertisement

Metastasen bei unbekanntem Primärtumor — „CUP-Syndrom“

  • I. Wildfang
  • H.-J. Schmoll
Chapter

Zusammenfassung

Patienten mit Metastasen von unbekannten Primärtumoren sind ein diagnostisches und therapeutisches Problem; ihr Anteil am Patientenkollektiv onkologischer Zentren beträgt 5% bis 10% [30, 41, 19]. „Metastasen bei unbekanntem Primärtumor“ sollten als eigenständiges Syndrom gekennzeichnet werden, da es sich in der Regel um eine besonders maligne biologische Ausdrucksform des — unbekannten -Primärtumors handelt und entsprechende spezifische diagnostische und therapeutische Vorgehensweisen erfordert. Dieses Syndrom wird im folgenden als „CUP-Syndrom“ (Carcinom mit unbekanntem Primärtumor; Carcinoma of Unknown Primary) bezeichnet [30, 28]; ein übliches Synonym ist „Metastasen bei unbekanntem Primärtumor“ (Metastases of Unknown Origin; „MUO“).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Altmannsberger M, Broese M (1984): Immunzytologische Klassifizierung von Metastasen bei unbekanntem Primärtumor. Verh Dtsch Ges Path 68:486Google Scholar
  2. 2.
    Batsakis JG (1981): The pathology of head and neck tumors. The occult primary and metastases to head and neck, part 10. Head Neck Surg 3:409–423PubMedCrossRefGoogle Scholar
  3. 3.
    Didolkar S, Fanous N, Elias EG, et al (1977): Metastatic carcinomas of occult primary tumors. A study of 254 cases. Ann Surg 186:625–630Google Scholar
  4. 4.
    Fer MF, Sherwin SA, Oldham RK, Greco FA, Matthews MJ (1982): Poorly differentiated Lung Cancer. Semin Oncol 9:456–466PubMedGoogle Scholar
  5. 5.
    Fer MF, Levenson RM, Cohen MH et al (1981): Extrapulmonary small cell carcinoma. In: Greco FA, Oldham RK, Bunn PA (eds) Small Cell Lung Cancer, Grune and Stratton New York, pp301–325Google Scholar
  6. 6.
    Feverman L, Attie JN, Rosenberg B (1962): Carcinoma in axillary lymph nodes. Surg Gynecol Obstet 114: 5 ffGoogle Scholar
  7. 7.
    Friedmann W, Steffens J, Lobeck H et al (1984): Immunhistochemische Charakterisierung von Metastasen des Prostatakarzinoms. Verh Dtsch Ges Path 68:115–117Google Scholar
  8. 8.
    Gatter KC, Mason DY (1982): The Use of Monoclonal Antibodies for Histopathologic Diagnosis of Human Malignancy. Semin Oncol 9:517–525PubMedGoogle Scholar
  9. 9.
    Gilbert HA, Kagan AR (1976): Metastases: Incidence, detection and evaluation without histologic confirmation. In: Weiss L (ed): Fundamental Aspects of Metastasis. New York, American Elsevier, pp 383–405Google Scholar
  10. 10.
    Giuliano AE, Alistair JC, Morton DL (1982): Melanoma from unknwon primary site and amelanotic melanoma. Semin Oncol 9:442–447PubMedGoogle Scholar
  11. 11.
    Goldberg R, Smith F, Meno W et al (1986): Treatment of Adenocarcinoma of unknown primary with Fluorouracil, Adriamycin and Mitomycin C (FAM). Proc Am Soc Clin Oncol 5:129Google Scholar
  12. 11a.
    Goldberg RM, Smith FP et al (1986): 5-Fluorouracil. Adriamycin, and Mitomycin in the Treatment of Adenocarcinoma of unknown Primary. J Clin Oncol 4: 395–399PubMedGoogle Scholar
  13. 12.
    Greco FA, Oldham RK, Fer FM (1982): The extragonadal Germ Cell Cancer Syndrome. Semin Oncol 9:448–455PubMedGoogle Scholar
  14. 13.
    Greenberg BR, Salom SE (1984): Human Tumor Clonogenic Assay in Patients with unknown Primary Carcinoma. J Clin Oncol 2:46–50PubMedGoogle Scholar
  15. 14.
    Hausher FH, Jarbro JW (1985): Diagnosis and Treatment of Malignant Pleural Effusion. Semin Oncol Vol 12:54–75Google Scholar
  16. 15.
    Johnson RO, Castro R, Ansfield R (1964): Response of primary unknown cancers to treatment with 5-Fluorouracil. Cancer Chemotherapy Rep 38:63–64Google Scholar
  17. 16.
    Jordan WE, Shildt RA (1985): Adenocarcinoma of unknown Primary Site. The Brooke Army Medical Center Experience. Cancer 55:857–860Google Scholar
  18. 17.
    Jundt G, Schulz A, Paul E et al (1984): S-100-Protein in amelanotischen malignen Melanomen. Verh Dtsch Ges Path 68:526Google Scholar
  19. 17a.
    Kambhu S, Kelsen D, et al (1986): Phase II trial of mitomycin C (M), Vindesine (D) and Adriamycin (A) and predictive variables in the treatment of patients (pts) with adenocarcinoma of unknown primary site (ACUP). Proc Am Assoc Cancer Res 27:185Google Scholar
  20. 18.
    Kehl A (1984): Bedeutung der Punktionszytologie für den Nachweis von Metastasen bei bekanntem oder unbekanntem Primärtumor aus der Sicht des Onkologen. Verh Dtsch Ges Path 68:479–480Google Scholar
  21. 19.
    Krementz ET, Cerise EJ, Ciaravella JM, et al (1977): Metastases of undetermined source. Cancer 27:289–300Google Scholar
  22. 20.
    Lainswoth JD, Greco FA (1986): Clinical characteristics of patients with advanced poorly differentiated carcinoma (PDG) and adenocarcinoma (PDA) of unknown primary who achieved complete response (CR) to combination chemotherapy. Proc Am Soc Clin Oncol 5:127Google Scholar
  23. 21.
    Le Chavalier Th, Smith FP et al (1985): Sites of primary malignancies in patients presenting with cerebral metastases. Cancer 56:880–882CrossRefGoogle Scholar
  24. 22.
    Le Chevalier T, Caille P et al (1985): Carcinoma of unknown primary. A study of 302 consecutive autopsied patients. Proc Am Soc Clin Oncol 4:8Google Scholar
  25. 23.
    Mackay B, Ordonez NG (1982): The Role of the Pathologist in the Evaluation of Poorly Differentiated Tumors. Semin Oncol 9:396–418PubMedGoogle Scholar
  26. 24.
    McGovern NJ (1975): Spontaneous regression of melanoma. Pathology 7:91–99PubMedCrossRefGoogle Scholar
  27. 25.
    Metz K, Richter HJ, Leder LD (1984): Immunhistochemische Befunde an großzelligen Lymphomen. Verh Dtsch Ges Path 68:448Google Scholar
  28. 26.
    Meyer JS (1982): Potential Value of Cell Kinetics in Management of Cancers of unknown origin. Semin Oncol 9:513–516PubMedGoogle Scholar
  29. 27.
    Mikuz G (1984): Retroperitoneale Lymphknotenmetastasen. Verh Dtsch Ges Path 68:485Google Scholar
  30. 28.
    Moertel CG, Reitermeier RJ, Schutt AJ, et al (1972): Treatment of the patient with adenocarcinoma of unknown origin. Cancer 30:1469–1472PubMedCrossRefGoogle Scholar
  31. 29.
    Müller HA (1984): Lymphknotenmetastasen in der Kopf-Hals-Region. Verh Dtsch Ges Path 68:481Google Scholar
  32. 30.
    Neumann KH, Nystrom JS (1982): Metastatic Cancer of unknown origin: Nonsquamous Cell Type. Semin Oncol 9:427–434PubMedGoogle Scholar
  33. 31.
    Nystrom JS, Weiner JM et al (1979): Identifying the primary site in metastatic cancer of unknown origin. JAMA 241:381–383PubMedCrossRefGoogle Scholar
  34. 32.
    Osteen RT, Kopf G, Wilson R (1978): In pursuit of the unknown primary. Am J Surg 135:494–497PubMedCrossRefGoogle Scholar
  35. 33.
    Pasterz R, et al (1985): Analysis of prognostic factors in patients with metastatic carcinoma of unknown primary. Proc ASCO 4:151Google Scholar
  36. 34.
    Pfützer P (194): Nachweis von Metastasen in Ergüssen der Körperhöhlen. Verh Dtsch Ges Path 68: 482Google Scholar
  37. 35.
    Richardson RL, Weiland LH (1982): Undifferentiated small cell carcinomas in extrapulmonary sites. Semin Oncol 9:484–496PubMedGoogle Scholar
  38. 36.
    Robert NJ, Garnick MB, Frei E (1982): Cancers of unknown origin, Current Approaches and Future Perspectives. Semin Oncol 9:526–531PubMedGoogle Scholar
  39. 37.
    Ruddon RW (1982): Tumor markers in the Recognition and Management of Poorly Differentiated Neoplasms and Cancers of unknown primary. Semin Oncol 9:416–426PubMedGoogle Scholar
  40. 38.
    Schaffer R, Müller HA, Osmanns U (1984): Immunzytochemische Befunde in Ausstrichpräparaten aus der Schilddrüse. Verh Dtsch Ges Path 68:497Google Scholar
  41. 39.
    Schrink-Moormann P, Schwerk U (1984): Lebermetastasen (Zytohisto-logische Untersuchungen). Verh Dtsch Ges Path 68:483Google Scholar
  42. 40.
    Schwarze EW (1983): Differentialdiagnose der malignen Lymphome unter besonderer Berücksichtigung der Non-Hodgkin-Lymphome. Diagnostik 16:32–34Google Scholar
  43. 40a.
    Shildt RA, Kennedy PS et al (1983): Management of patients with metastatic adenocarcinoma of unknown origin: A Southwest oncology Group study. Cancer Treat Rep. 67:77–79PubMedGoogle Scholar
  44. 41.
    Silverman C, Marks JE (1982): Metastatic Cancer of unknown origin: Epidermoid and Undifferentiated Carcinoma. Semin Oncol 9:435–441PubMedGoogle Scholar
  45. 42.
    Sprenger E (1984): Risiko der Metastasierung bei Feinnadelpunktionen. Verh Dtsch Ges Path 68:487Google Scholar
  46. 43.
    Staub E, Jungi WF, Gloar F, Senn HJ (1981): Lymphknotenmetastasen bei unbekanntem Primärtumor: Sinn und Unsinn einer breiten Abklärung. Schweiz med Wschr 111:1298–1300PubMedGoogle Scholar
  47. 44..
    Heyden v. HW, Hansen D, Kaboth GA, Hoffmann H, Schneider (1984): Metastasierendes Adenokarzinom bei unbekanntem Primärtumor. Dtsch med Wschr 109:15–19CrossRefGoogle Scholar
  48. 45..
    Walach U (1986): Treatment of adenocarcinoma of unknown origin with cylophosphamide (C), Oncovin (O), Methotrexate (M) and 5-Fluorouracil (F) (COMF). Proc Am Soc Clin Oncol 5:125Google Scholar
  49. 46..
    Woods RL, Fox RM, et al (1980): Metastatic adenocarcinomas of unknown primary site. N Engl J Med 303:87–89PubMedCrossRefGoogle Scholar
  50. 47..
    York JC, Glick AD, Collins RD (1982): Unclassified Leukemias and Lymphomas. Semin Oncol 9:497–503PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • I. Wildfang
  • H.-J. Schmoll

There are no affiliations available

Personalised recommendations